Novartis AG NVSEF OTC

Novartis AG (NVSEF) reported total assets of $115.49B and total liabilities of $68.97B for fiscal year 2025, resulting in total equity of $46.52B.

The company held $11.58B in cash and short-term investments. Total debt stood at $37.01B, with net debt of $25.58B. The Debt-to-Equity (D/E) ratio was 0.8 (moderate).

Current ratio is 1.12, suggesting adequate short-term liquidity. Interest coverage is 14.4x (strong).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (94/100) — Total assets $115.49B and equity $46.52B support the company's competitive scale
• VALUE (75/100) — Debt-to-Equity 0.8 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 73/100 with 5/7 criteria passed.

RHHBF

Roche Holding AG

$418.50

+1.82%

RHHBY

Roche Holding AG

$51.02

+0.65%

RHHVF

Roche Holding AG

$403.29

+8.69%

AZN

AstraZeneca PLC

$204.38

+1.06%

NVS

Novartis AG

$153.38

-0.71%

AZNCF

AstraZeneca PLC

$189.90

-1.35%

GSK

GSK plc

$59.18

+0.41%

SNY

Sanofi

$47.64

+1.45%